298380.KQ
ABL Bio Inc.
KOE · Healthcare · Medical - Pharmaceuticals · KR
KRW 67,600.00
−2.45%Year over year
Reported trailing growth
- Revenue
- -63.9%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- -5.4%
- Operating cash flow
- -77.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +5.6%
- EBITDA
- +30.5%
- EBIT
- +32.0%
- Net income
- +31.8%
- EPS
- +39.2%
- Free cash flow
- +21.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026